within Pharmacolibrary.Drugs.ATC.N;

model N02AD01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.3333333333333335e-05,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00195,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0052,
    k12             = 0.8,
    k21             = 0.8
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02AD01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Pentazocine is a synthetic opioid analgesic that acts as an agonist-antagonist at opioid receptors. It is used for the management of moderate to moderately severe pain. While it was once widely used, its clinical use has declined due to adverse effects and abuse potential, and it is less commonly used today in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single intravenous and oral doses.</p><h4>References</h4><ol><li><p>Kudo, T, et al., &amp; Matsuki, A (1992). [Pharmacokinetics of ketamine and pentazocine during total intravenous anesthesia with droperidol, pentazocine and ketamine]. <i>Masui. The Japanese journal of anesthesiology</i> 41(11) 1772–1776. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1460754/\">https://pubmed.ncbi.nlm.nih.gov/1460754</a></p></li><li><p>Suzuki, T, et al., &amp; Hanano, M (1997). Pharmacokinetics of pentazocine and its occupancy of opioid receptors in rat brain. <i>Biological &amp; pharmaceutical bulletin</i> 20(11) 1193–1198. DOI:<a href=\"https://doi.org/10.1248/bpb.20.1193\">10.1248/bpb.20.1193</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9401731/\">https://pubmed.ncbi.nlm.nih.gov/9401731</a></p></li><li><p>Hamunen, K, et al., &amp; Maunuksela, EL (1993). Pharmacokinetics and pharmacodynamics of pentazocine in children. <i>Pharmacology &amp; toxicology</i> 73(2) 120–123. DOI:<a href=\"https://doi.org/10.1111/j.1600-0773.1993.tb01547.x\">10.1111/j.1600-0773.1993.tb01547.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8248007/\">https://pubmed.ncbi.nlm.nih.gov/8248007</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02AD01;
